PubMed

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR; Ragaglitazar Dose-Ranging Study Group.

Diabetes Care. 2004 Jun;27(6):1324-9.PMID: 15161783 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.PMID: 17166340 [PubMed - indexed for MEDLINE]Related articles

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA.

Diabetes Care. 2006 May;29(5):1016-23.PMID: 16644631 [PubMed - indexed for MEDLINE]Related articlesFree article

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.

Diabetes Care. 2000 Nov;23(11):1605-11.PMID: 11092281 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

Coron Artery Dis. 2001 Aug;12(5):413-23.PMID: 11491207 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

Clin Ther. 2000 Dec;22(12):1395-409.PMID: 11192132 [PubMed - indexed for MEDLINE]Related articles

A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group.

Int J Clin Pract. 2002 May;56(4):251-7.PMID: 12074206 [PubMed - indexed for MEDLINE]Related articles

Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.

Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B.

J Clin Pharmacol. 2003 Nov;43(11):1244-56.PMID: 14551179 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL.

Am J Med. 2001 Jul;111(1):10-7.PMID: 11448655 [PubMed - indexed for MEDLINE]Related articles

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldórsdóttir S, Gause-Nilsson I.

Diabetologia. 2005 Sep;48(9):1716-25. Epub 2005 Jul 7.PMID: 16001233 [PubMed - indexed for MEDLINE]Related articles

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.PMID: 16860259 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

Berhanu P, Perez A, Yu S.

Diabetes Obes Metab. 2007 Jul;9(4):512-20.PMID: 17587394 [PubMed - indexed for MEDLINE]Related articles